DoD Bone Marrow Failure, Investigator-Initiated Research Award
The FY24 BMFRP Investigator-Initiated Research Award (IIRA) will offer two funding levels with different intent:Funding Level 1 (FL1):
To support studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in the FY24 BMFRP Focus Areas.
IIRA applications may involve translational and clinical research including studies in animal models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, FL1 awards may not be used to support a clinical trial.
An application that proposes a correlative study should be associated with a clinical trial(s), and the proposed study should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or other impactful outcomes.
Multidisciplinary collaborations are encouraged.Funding Level 2 (FL2):
To support Investigational New Drug (IND) application-enabling efforts.
The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation.
Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence.
The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate that will be included in an IND application submission to the U. S. Food and Drug Administration (FDA).
At least one and no more than three lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism.
Library screening or drug optimization studies do not meet the intent of FL 2. The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism.
FL2 applications must address the FY24 BMFRP Focus Area, “Find effective BMF treatments and cures.”
To support studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in the FY24 BMFRP Focus Areas.
IIRA applications may involve translational and clinical research including studies in animal models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, FL1 awards may not be used to support a clinical trial.
An application that proposes a correlative study should be associated with a clinical trial(s), and the proposed study should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or other impactful outcomes.
Multidisciplinary collaborations are encouraged.Funding Level 2 (FL2):
To support Investigational New Drug (IND) application-enabling efforts.
The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation.
Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence.
The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate that will be included in an IND application submission to the U. S. Food and Drug Administration (FDA).
At least one and no more than three lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism.
Library screening or drug optimization studies do not meet the intent of FL 2. The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism.
FL2 applications must address the FY24 BMFRP Focus Area, “Find effective BMF treatments and cures.”
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://grants.hrsa.gov/webExternal/SFO.asp?ID=90E776E8-4C99-430F-B46C-31A440AEAB25
Additional Information of Eligibility:
All applicants, including current grantees, must document Medicaid provider status.
Applicants may document formal agreements with Medicaid providers for provision of all services covered under the Medicaid State plan.
This requirement may be waived for free clinics that do not impose a charge for health services and do not accept reimbursement from Medicaid, Medicare, or private insurance.
All applicants, including current grantees, must document that they are fully licensed to provide clinical services, as required by their State and/or local jurisdiction.
Medicaid provider status and licensure must be in place prior to submitting an application.
Full Opportunity Web Address:
https://grants.hrsa.gov/webExternal/SFO.asp?ID=90E776E8-4C99-430F-B46C-31A440AEAB25
Contact:
Agency Email Description:
CDMRP Help Desk
Agency Email:
Date Posted:
2024-06-07
Application Due Date:
Archive Date:
2024-11-08
Social Entrepreneurship
Spotlight
Rwanda as Social Entrepreneur Fund Beneficiary
The Republic of Rwanda has been picked as one of the six African countries as beneficiaries for a new fellowship fund program designed at supporting social entrepreneurs in tackling issues on food security.
Learn How to Identify and Avoid Grant Scams
